THE COMPLEXITIES software on Facebook has more than 85 million users who’ve created over 300,000 charitable causes that have benefited 60,000 nonprofits in the United Canada and States. Donors have used the Causes program on Facebook to provide a lot more than $14 million to these businesses. Before the release of Aflac’s pediatric malignancy Cause, the largest coordinating grant on a Facebook Cause was $100,000. ‘Thanks to Aflac’s campaign to raise money for childhood malignancy and blood disorders on Causes on Facebook, children at the Aflac Malignancy Center will be assured cutting edge treatment and clinical research to have them back to being kids,’ said Dr. William G. Woods, Director of the Aflac Cancer Center. ‘With every dollar elevated we offer fresh hope for our kids and their own families.’ Related StoriesCrucial switch in single DNA bottom predisposes children to aggressive form of cancerViralytics enters into medical trial collaboration contract with MSDNew findings reveal association between colorectal cancer tumor and melanoma medications’Our goal is to find a cure,’ said Aflac CEO and chairman Dan Amos.Under the conditions of the contract, Allergan will acquire AqueSys for a $300 million upfront payment and regulatory authorization and commercialization milestone payments related to AqueSys' lead development applications, including XEN45. The acquisition of AqueSys and its own XEN45 system builds on Allergan's long-standing and deep dedication to innovation in eyesight care, said Brent Saunders, President and CEO of Allergan. Our eyes care team has a strong track record of introducing novel treatments for individuals with glaucoma. The acquisition of the XEN45 device demonstrates our dedication to alternative next-era glaucoma remedies which are attractive to both sufferers and doctors and extend beyond standard medicine eyedrops.